Terms: = Brain cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2
604 results:
1. Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype.
Dundar B; Alsawas M; Masaadeh A; Conway K; Snow AN; Sompallae RR; Bossler AD; Ma D; Lopes Abath Neto O
Pathol Res Pract; 2024 May; 257():155272. PubMed ID: 38631135
[TBL] [Abstract] [Full Text] [Related]
2. EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization.
Wilcock DM; Goold E; Zuromski LM; Davidson C; Mao Q; Sirohi D
J Neuropathol Exp Neurol; 2024 Apr; 83(5):338-344. PubMed ID: 38605523
[TBL] [Abstract] [Full Text] [Related]
3. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases.
Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R
Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367
[TBL] [Abstract] [Full Text] [Related]
4. Perifocal edema is a risk factor for preoperative seizures in patients with meningioma WHO grade 2 and 3.
Teske N; Teske NC; Greve T; Karschnia P; Kirchleitner SV; Harter PN; Forbrig R; Tonn JC; Schichor C; Biczok A
Acta Neurochir (Wien); 2024 Apr; 166(1):170. PubMed ID: 38581569
[TBL] [Abstract] [Full Text] [Related]
5. High expression of RTEL1 predicates worse progression in gliomas and promotes tumorigenesis through JNK/ELK1 cascade.
Wang G; Ren X; Li J; Cui R; Zhao X; Sui F; Liu J; Chen P; Yang Q; Ji M; Hou P; Gao K; Qu Y
BMC Cancer; 2024 Mar; 24(1):385. PubMed ID: 38532312
[TBL] [Abstract] [Full Text] [Related]
6. STING is significantly increased in high-grade glioma with high risk of recurrence.
Zhong M; Long M; Han C; Ji S; Yang Q
Oncoimmunology; 2024; 13(1):2327682. PubMed ID: 38516268
[TBL] [Abstract] [Full Text] [Related]
7. Predicting the prognosis of glioma patients with tert promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
[TBL] [Abstract] [Full Text] [Related]
8. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib.
Cabezas-Camarero S; García-Barberán V; Pérez-Alfayate R; Gómez Del Pulgar ME; Cabrera-Martin MN; Casado-Fariñas I; Pérez-Segura P
Oncologist; 2024 May; 29(5):377-383. PubMed ID: 38438322
[TBL] [Abstract] [Full Text] [Related]
9. Genomic drivers in craniopharyngiomas: Analysis of the AACR project GENIE database.
Lehrich MB; Tong CLC; Hsu PKF; Kuan CE
Childs Nerv Syst; 2024 Jun; 40(6):1661-1669. PubMed ID: 38421446
[TBL] [Abstract] [Full Text] [Related]
10. Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study.
Xi S; Jiang S; Li H; Huang Q; Lu J; Zhang X; Li Z; Zeng J
Int J Cancer; 2024 Jul; 155(1):172-183. PubMed ID: 38411299
[TBL] [Abstract] [Full Text] [Related]
11. MGMT unmethylation and high levels of CD47 and TIGIT indicate a poor prognosis in adult diffuse gliomas.
Ma L; Shi Y; Li C; Deng B; Jiang J; Cao Y; Wang L; Li H
Front Immunol; 2024; 15():1323307. PubMed ID: 38404571
[TBL] [Abstract] [Full Text] [Related]
12. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
[TBL] [Abstract] [Full Text] [Related]
13. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
[TBL] [Abstract] [Full Text] [Related]
14. Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas.
Liang Q; Jing H; Shao Y; Wang Y; Zhang H
Clin Neuroradiol; 2024 Mar; 34(1):33-43. PubMed ID: 38277059
[TBL] [Abstract] [Full Text] [Related]
15. Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors.
On J; Natsumeda M; Takahashi H; Koyama A; Shibuma S; Shibata N; Watanabe J; Saito S; Kanemaru Y; Tsukamoto Y; Okada M; Ogura R; Eda T; Tada M; Shimizu H; Adachi JI; Mishima K; Nishikawa R; Kakita A; Oishi M
J Neurooncol; 2024 Jan; 166(2):273-282. PubMed ID: 38227143
[TBL] [Abstract] [Full Text] [Related]
16. The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?
Di Nunno V; Aprile M; Bartolini S; Gatto L; Tosoni A; Ranieri L; De Biase D; Asioli S; Franceschi E
Cells; 2023 Dec; 13(1):. PubMed ID: 38201248
[TBL] [Abstract] [Full Text] [Related]
17. Whole tumor analysis reveals early origin of the tert promoter mutation and intercellular heterogeneity in tert expression.
Appin CL; Hong C; Suwala AK; Hilz S; Mathur R; Solomon DA; Smirnov IV; Stevers NO; Shai A; Wang A; Berger MS; Chang SM; Phillips JJ; Costello JF
Neuro Oncol; 2024 Apr; 26(4):640-652. PubMed ID: 38141254
[TBL] [Abstract] [Full Text] [Related]
18. [Practical approach to molecular pathology of central nervous system tumours].
Vida L; Horváth B; Kajtár B
Magy Onkol; 2023 Dec; 67(4):304-313. PubMed ID: 38109509
[TBL] [Abstract] [Full Text] [Related]
19. Longitudinal trajectory of amplitude of low-frequency fluctuation changes in breast cancer patients during neoadjuvant chemotherapy-A preliminary prospective study.
Hu Y; Yu H; Lai Y; Liu J; Tan Y; Lei W; Zhang J; Zhou X; Cao Y; Tang Y; Liu D; Zhang J
Brain Res Bull; 2024 Jan; 206():110845. PubMed ID: 38101650
[TBL] [Abstract] [Full Text] [Related]
20. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
[TBL] [Abstract] [Full Text] [Related]
[Next]
